{"id":62875,"date":"2026-04-01T07:02:37","date_gmt":"2026-04-01T05:02:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/"},"modified":"2026-04-01T07:02:37","modified_gmt":"2026-04-01T05:02:37","slug":"revolka-reimagines-antibody-engineering-with-revoab","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/","title":{"rendered":"RevolKa Reimagines Antibody Engineering with &#8220;RevoAb\u00ae&#8221;"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa\u2019s advanced AI Protein Engineering Engine<\/i><\/p>\n<p>SENDAI, Japan&#8211;(BUSINESS WIRE)&#8211;RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called <b><i>ai<\/i>Protein<sup>\u00ae<\/sup><\/b>, is pleased to announce the official global launch of <b>RevoAb<sup>\u00ae<\/sup><\/b>, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially <b>antibody<\/b> <b>yields<\/b>.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260324326476\/en\/2759057\/5\/RevoAb_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260324326476\/en\/2759057\/22\/RevoAb_logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260324326476\/en\/2759057\/5\/RevoAb_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260324326476\/en\/2759057\/21\/RevoAb_logo.jpg\"><\/a><\/p>\n<p>\n<b>RevoAb<\/b><sup>\u00ae<\/sup><b>:<\/b> <b>The Next-Gen AI Antibody Design<\/b><\/p>\n<p>\nSince December 2023, RevolKa has provided an antibody optimization services utilizing <i>ai<\/i>Protein\u00ae. The newly launched <b>RevoAb<sup>\u00ae<\/sup><\/b> is a quick intuitive online antibody sequence optimization service that integrates RevolKa\u2019s core technology\u2014the<b> &#8220;Refined Naturalness Framework Engineering&#8221;<\/b>. <b>RevoAb<sup>\u00ae<\/sup><\/b> is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially <b>protein expression levels<\/b>, without trade-off of affinity. This allows researchers worldwide to experience RevolKa\u2019s high-performance antibody design.<\/p>\n<p>\n<b>Key Advantages of RevoAb<sup>\u00ae<\/sup><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Speed: <\/b>Multiple optimized sequence candidates for improved physicochemical properties<b> in a day, not weeks<\/b><\/li>\n<li>\n<b>Satisfaction<\/b>: Proven records, <b>92% success rate<\/b>, by Japanese pharmaceutical and academic customers (including internal data), particularly with significant improvements in protein expression levels during the pre-launch period beginning July 2025<\/li>\n<li>\n<b>Low cost<\/b>: Starting at <b>$700 USD<\/b> per antibody for exploring physicochemical property improvements, <b>\u201cStart with RevoAb<sup>\u00ae<\/sup>, Scale with <i>ai<\/i>Protein<sup>\u00ae <\/sup><\/b>, high-value, fully customized AI antibody engineering\u201d<\/li>\n<li>\n<b>ZERO Complex AI Configurations<\/b>: No specialized AI and bioinformatics expertise and expert-level AI parameter tuning, making advanced AI design accessible to every researcher<\/li>\n<li>\n<b>High Modality and Species Compatibility<\/b>: Wide-Range of antibody modalities, from monoclonal IgG to the next-gen antibodies, such as variable fragment formats (Fv, VHH) across diverse species including human, mouse, rat, rabbit, chicken, llama, etc.<\/li>\n<\/ul>\n<p>\nFor details, visit the RevoAb<sup>\u00ae<\/sup> Service Site: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Frevoab.revolka.com%2Fen%2F&amp;esheet=54461564&amp;newsitemid=20260324326476&amp;lan=en-US&amp;anchor=https%3A%2F%2Frevoab.revolka.com%2Fen%2F&amp;index=1&amp;md5=31edc494dd6e6212255c98495e9af707\" rel=\"nofollow\" shape=\"rect\">https:\/\/revoab.revolka.com\/en\/<\/a><\/p>\n<p>\n<b>Proven Success in Japan<\/b><\/p>\n<p>\nThroughout the pilot phase, RevoAb<sup>\u00ae<\/sup> has successfully contributed to solving critical challenges for Japanese pharmaceutical companies, biotech ventures, and universities. The service has earned a strong reputation for its ability, for example, to overcome production issues. An example is shown below. One of the three RevoAb generated sequences of a difficult-to-express single chain Fv showed 7x higher expression levels in E.coli without serious change in affinity.<\/p>\n<p>\n<b>Background: Minimizing Lead Time and R&amp;D Costs<\/b><\/p>\n<p>\nAntibodies are essential across various industries, from therapeutics to diagnostics. However, optimizing their characteristics, such as stability, affinity, and productivity, remains a significant technical hurdle requiring substantial time and investment.<\/p>\n<p>\nRevolKa helps to break these barriers by providing researchers worldwide with direct, simple access to the power of <b><i>ai<\/i>Protein<sup>\u00ae<\/sup><\/b>. By streamlining the design process, <b>RevoAb<sup>\u00ae<\/sup><\/b> empowers scientists to focus on breakthrough discoveries.<\/p>\n<p>\n<b>About RevolKa Ltd.<\/b><\/p>\n<p>\nRevolKa is a biotechnology company specialized in protein engineering using its proprietary AI platform, <i>ai<\/i>Protein<sup>\u00ae<\/sup>. The company is committed to accelerating the development of novel biologics and industrial enzymes to improve human health and sustainability.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nInquiries Regarding RevoAb<sup>\u00ae<\/sup><br \/>For any question, please contact us at <a target=\"_blank\" href=\"&#109;&#97;&#x69;&#x6c;&#116;&#111;&#x3a;&#x73;&#117;&#112;&#x70;&#x6f;&#114;&#116;&#x2d;&#x72;&#101;&#118;&#x6f;&#x74;&#117;&#110;&#x65;&#x40;&#114;&#101;&#x76;&#x6f;&#108;&#107;&#x61;&#x2e;&#99;&#111;&#x2e;&#x6a;&#112;\" rel=\"nofollow\" shape=\"rect\">&#115;&#x75;&#x70;p&#111;&#x72;t&#45;&#x72;&#x65;&#118;&#x6f;&#x74;u&#110;&#x65;&#64;&#114;&#x65;&#x76;&#111;&#x6c;&#x6b;a&#46;&#x63;o&#46;&#x6a;&#x70;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa\u2019s advanced AI Protein Engineering Engine SENDAI, Japan&#8211;(BUSINESS WIRE)&#8211;RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein\u00ae, is pleased to announce the official global launch of RevoAb\u00ae, an innovative and quick online service for antibody sequence &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62875","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>RevolKa Reimagines Antibody Engineering with &quot;RevoAb\u00ae&quot; - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RevolKa Reimagines Antibody Engineering with &quot;RevoAb\u00ae&quot; - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa\u2019s advanced AI Protein Engineering Engine SENDAI, Japan&#8211;(BUSINESS WIRE)&#8211;RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein\u00ae, is pleased to announce the official global launch of RevoAb\u00ae, an innovative and quick online service for antibody sequence ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T05:02:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260324326476\/en\/2759057\/22\/RevoAb_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-reimagines-antibody-engineering-with-revoab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-reimagines-antibody-engineering-with-revoab\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"RevolKa Reimagines Antibody Engineering with &#8220;RevoAb\u00ae&#8221;\",\"datePublished\":\"2026-04-01T05:02:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-reimagines-antibody-engineering-with-revoab\\\/\"},\"wordCount\":481,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-reimagines-antibody-engineering-with-revoab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260324326476\\\/en\\\/2759057\\\/22\\\/RevoAb_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-reimagines-antibody-engineering-with-revoab\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-reimagines-antibody-engineering-with-revoab\\\/\",\"name\":\"RevolKa Reimagines Antibody Engineering with \\\"RevoAb\u00ae\\\" - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-reimagines-antibody-engineering-with-revoab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-reimagines-antibody-engineering-with-revoab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260324326476\\\/en\\\/2759057\\\/22\\\/RevoAb_logo.jpg\",\"datePublished\":\"2026-04-01T05:02:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-reimagines-antibody-engineering-with-revoab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-reimagines-antibody-engineering-with-revoab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-reimagines-antibody-engineering-with-revoab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260324326476\\\/en\\\/2759057\\\/22\\\/RevoAb_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260324326476\\\/en\\\/2759057\\\/22\\\/RevoAb_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-reimagines-antibody-engineering-with-revoab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RevolKa Reimagines Antibody Engineering with &#8220;RevoAb\u00ae&#8221;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RevolKa Reimagines Antibody Engineering with \"RevoAb\u00ae\" - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/","og_locale":"en_US","og_type":"article","og_title":"RevolKa Reimagines Antibody Engineering with \"RevoAb\u00ae\" - Pharma Trend","og_description":"A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa\u2019s advanced AI Protein Engineering Engine SENDAI, Japan&#8211;(BUSINESS WIRE)&#8211;RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein\u00ae, is pleased to announce the official global launch of RevoAb\u00ae, an innovative and quick online service for antibody sequence ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/","og_site_name":"Pharma Trend","article_published_time":"2026-04-01T05:02:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260324326476\/en\/2759057\/22\/RevoAb_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"RevolKa Reimagines Antibody Engineering with &#8220;RevoAb\u00ae&#8221;","datePublished":"2026-04-01T05:02:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/"},"wordCount":481,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260324326476\/en\/2759057\/22\/RevoAb_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/","url":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/","name":"RevolKa Reimagines Antibody Engineering with \"RevoAb\u00ae\" - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260324326476\/en\/2759057\/22\/RevoAb_logo.jpg","datePublished":"2026-04-01T05:02:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260324326476\/en\/2759057\/22\/RevoAb_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260324326476\/en\/2759057\/22\/RevoAb_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/revolka-reimagines-antibody-engineering-with-revoab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"RevolKa Reimagines Antibody Engineering with &#8220;RevoAb\u00ae&#8221;"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62875"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62875\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}